Responses

PDF

Research paper
Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Dosing regimen of oral prednisolone and prognosis in patients with generalized myasthenia gravis

    Imai et al. examined the association between the dosing regimen of oral prednisolone (PSL) and the achievement of minimal manifestation status or better on PSL <=5 mg/day lasting >6 months in patients with generalized myasthenia gravis (1). The authors classified 590 patients into high-dose, intermediate-dose and low-dose (n=166) groups, and logistic regression analysis was applied to know the prognosis of patients in low-dose group, by splitting observational period into 1 to 3 years of treatment. The authors concluded that a low-dose PSL regimen with early combination of other treatment options was significantly associated with good prognosis. I have two concerns about their study.

    First, the dosing regimen of oral PSL should be considered with caution. Namely, the authors set the maximum dose of oral PSL in each group, and standard treatment schedule was selected after each patient was allocated. Mean daily dose of PSL does not become highest in high-dose group in the study, which happens in the study protocol. In addition, there is a possibility of higher frequency in patients with combination of other treatment options, when patients were registered into low-dose group. As the age of onset was higher and disease duration was shorter in patients with low-dose group, randomized allocation should be strictly conducted in further study.

    Second, the number of events was not enough after 1 year observation, and higher odds ratios with wide ranges of con...

    Show More
    Conflict of Interest:
    None declared.